Log in

NASDAQ:CANF - Can-Fite Biopharma Stock Price, Forecast & News

-0.01 (-0.74 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
Now: $1.34
50-Day Range
MA: $1.47
52-Week Range
Now: $1.34
Volume364,200 shs
Average Volume934,380 shs
Market Capitalization$11.62 million
P/E RatioN/A
Dividend YieldN/A
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.
Read More

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:CANF



Sales & Book Value

Annual SalesN/A



Market Cap$11.62 million
Next Earnings DateN/A

Receive CANF News and Ratings via Email

Sign-up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter.

Can-Fite Biopharma (NASDAQ:CANF) Frequently Asked Questions

How has Can-Fite Biopharma's stock been impacted by COVID-19 (Coronavirus)?

Can-Fite Biopharma's stock was trading at $1.52 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CANF shares have decreased by 11.8% and is now trading at $1.34. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Can-Fite Biopharma?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Can-Fite Biopharma in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A." View analyst ratings for Can-Fite Biopharma.

Has Can-Fite Biopharma been receiving favorable news coverage?

Headlines about CANF stock have been trending negative on Saturday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Can-Fite Biopharma earned a coverage optimism score of -2.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the company's share price in the next few days. View the latest news aboutCan-Fite Biopharma.

Who are some of Can-Fite Biopharma's key competitors?

What other stocks do shareholders of Can-Fite Biopharma own?

Who are Can-Fite Biopharma's key executives?

Can-Fite Biopharma's management team includes the following people:
  • Prof. Pnina Fishman Ph.D., Scientific Founder, Chief Exec. Officer & Director (Age 70)
  • Mr. Motti Farbstein, Chief Operating & Financial Officer (Age 54)
  • Dr. Ilan Cohn Ph.D., Co-Founder & Chairman (Age 64)
  • Dr. Michael H. Silverman M.D., F.A.C.P.,FACR, Medical Director
  • Dr. Vibeke Strand M.D., FACP, FACR (USA), Sr. Clinical Advisor

What is Can-Fite Biopharma's stock symbol?

Can-Fite Biopharma trades on the NASDAQ under the ticker symbol "CANF."

How do I buy shares of Can-Fite Biopharma?

Shares of CANF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Can-Fite Biopharma's stock price today?

One share of CANF stock can currently be purchased for approximately $1.34.

How big of a company is Can-Fite Biopharma?

Can-Fite Biopharma has a market capitalization of $11.62 million.  View additional information about Can-Fite Biopharma.

What is Can-Fite Biopharma's official website?

The official website for Can-Fite Biopharma is http://www.canfite.co.il/.

MarketBeat Community Rating for Can-Fite Biopharma (NASDAQ CANF)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  102 (Vote Outperform)
Underperform Votes:  104 (Vote Underperform)
Total Votes:  206
MarketBeat's community ratings are surveys of what our community members think about Can-Fite Biopharma and other stocks. Vote "Outperform" if you believe CANF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CANF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel